2014
Guanfacine extended release for the treatment of attention-deficit/hyperactivity disorder in children and adolescents
Connor DF, Arnsten A, Pearson GS, Greco GF. Guanfacine extended release for the treatment of attention-deficit/hyperactivity disorder in children and adolescents. Expert Opinion On Pharmacotherapy 2014, 15: 1601-1610. PMID: 24992513, DOI: 10.1517/14656566.2014.930437.Peer-Reviewed Original ResearchConceptsAttention-deficit/hyperactivity disorderHyperactivity disorderSymptoms of ADHDEvidence-based treatmentsTraumatic stressBehavioral dysregulationADHD studiesSmall effect sizesPrefrontal cortexAdolescents 6Behavioral conditionsAdolescentsEffect sizeGXRPsycINFO databasesGuanfacinePsychostimulantsShire PharmaceuticalsOpen trialChildrenPotential promiseSecond-line treatmentDisordersAntihypertensive agentsAdrenoreceptor agonist
1999
Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder
Southwick S, Bremner J, Rasmusson A, Morgan C, Arnsten A, Charney D. Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder. Biological Psychiatry 1999, 46: 1192-1204. PMID: 10560025, DOI: 10.1016/s0006-3223(99)00219-x.Peer-Reviewed Original ResearchConceptsRole of norepinephrineClinical studiesNorepinephrine's roleTrauma-related alterationsRe-experiencing symptomsFear-provoking stimuliTreatment of PTSDPosttraumatic stress disorderChronic uncontrollable stressPharmacologic treatmentClinical findingsNeuronal reactivityIntrusive memoriesAdrenergic blockersEnhanced encodingSelective attentionPreclinical studiesReceptor sensitivityAversive eventsNorepinephrineTraumatic stressNovel stimuliStress disorderMAO inhibitorsUncontrollable stress